Infusion Therapy Insurance Denial Appeal — Free AI Letter
Insurance denied your home or hospital infusion therapy or forced a site-of-care change? Generate a free appeal letter citing your plan's policy in minutes.
Why infusion therapy denials happen so often
Infusion therapy delivers medications, fluids, or nutrition intravenously, subcutaneously, or through other parenteral routes. The clinical scope ranges from immune globulin (IVIG/SCIG) for primary immunodeficiency, to biologic infusions for rheumatoid arthritis (Remicade/infliximab) and inflammatory bowel disease (Entyvio/vedolizumab), to chemotherapy, to home antibiotic regimens, to enteral and parenteral nutrition. The most common denial pattern is no longer outright coverage refusal but rather a forced site-of-care change: insurers now routinely require infusion drugs that were previously administered in a hospital outpatient department to be delivered at a contracted ambulatory infusion center, in the prescriber's office, or at home. This 'site of care' policy can produce a denial when the patient continues at the higher-cost site. The denial is appealable when the alternative site is not clinically appropriate for the specific patient or when the alternative network is inadequate.
Why Infusion gets denied
Site-of-care policy: medication approved but only at a lower-cost site (home, AIC, or prescriber office)
Step therapy: patient required to fail a lower-cost biologic or biosimilar first
Prior authorization not obtained or expired
Drug administered for an off-label indication not on the plan's approved list
Specialty pharmacy network restrictions - drug must be sourced from a specific specialty pharmacy contracted with the plan or PBM
Frequency of infusion exceeds plan's clinical policy
Coverage gap during plan transition or formulary change
Preferred biosimilar not used - some plans now mandate Inflectra, Renflexis, or Avsola over branded Remicade
Federal and state protections for Infusion
Infusion therapy coverage is governed by your plan's medical and pharmacy benefit contracts. ACA-regulated plans must provide internal appeal and external review under 45 CFR section 147.136. Self-funded ERISA plans are bound by 29 CFR section 2560.503-1 full-and-fair-review requirements. Medicare Part B covers physician-administered infusion drugs under the Average Sales Price methodology in 42 USC section 1395w-3a; the National Home Infusion Therapy benefit was added under the 21st Century Cures Act and is implemented at 42 CFR section 414.1500. State step-therapy reform laws now in effect in more than 30 states (e.g. New York Public Health Law section 4910, California Health and Safety Code section 1367.244) require expedited exception processes when step therapy is medically inappropriate. The federal No Surprises Act (42 USC sections 300gg-111 et seq.) protects against surprise out-of-network billing if the infusion site is in-network but the administering provider was not.
Evidence checklist for your appeal
- Letter of medical necessity from the prescribing physician explaining why the requested drug, frequency, and site of care are required
- Documentation of failed alternatives if step therapy is at issue (drug name, dose, duration, reason for failure or intolerance)
- Plan's specific clinical policy or medical drug policy with the relevant criteria-met paragraph identified
- Manufacturer prescribing information for the drug if dosing or frequency is contested
- Peer-reviewed literature supporting the clinical regimen, especially for off-label indications listed in DrugDex, NCCN, or AHFS compendia (which Medicare and many commercial plans recognize)
- If site-of-care denial: documentation of why the requested site is clinically necessary (vascular access difficulty, infusion reaction history, distance from alternative sites, caregiver availability for home infusion)
- If state step-therapy law applies: citation of the state statute and a request for expedited exception
Common billing codes
- 96365 (IV infusion, initial up to 1 hour)
- 96366 (each additional hour)
- 96367 (additional sequential infusion)
- 96369-96371 (subcutaneous infusion)
- 96374 (IV push, single drug)
- Q5103 (infliximab-dyyb, Inflectra)
- J1745 (infliximab, Remicade, 10 mg)
- J3380 (vedolizumab, Entyvio)
Common products
- Remicade (infliximab)
- Inflectra, Renflexis, Avsola (infliximab biosimilars)
- Entyvio (vedolizumab)
- Tysabri (natalizumab)
- Ocrevus (ocrelizumab)
- Rituxan (rituximab)
- Privigen, Gammagard, Gamunex-C (IVIG)
Insurer-specific patterns and tactics
Anthem and other Elevance Health plans have been particularly active on home and AIC site-of-care policies for biologic infusions, with policies updated periodically that move drugs from hospital outpatient to lower-cost sites. UnitedHealthcare similarly applies site-of-service policies through Optum. Cigna's Evernorth specialty pharmacy unit (Accredo) is the contracted specialty pharmacy for many specialty infusion drugs, and using a different pharmacy can produce a network denial. CVS/Aetna routes specialty pharmacy through CVS Specialty. State step-therapy laws have been increasingly invoked successfully against PBMs that apply rigid step protocols.
Generate your Infusion appeal letter
Upload your denial notice or EOB. Our 5-agent AI pipeline drafts a professional appeal that cites the specific statute, clinical policy, and evidence pattern relevant to a infusion denial - in about 2 minutes, free.
Upload my denial · Free